AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00575848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glycine
Description: Subjects will consume glycine twice daily, once with breakfast and once with dinner. The medication is in liquid form. They will be instructed to refrigerate the liquid until the time that they take it. Subjects start by taking 10g per day for the first 2 days. Starting on the 3rd day, subjects take 0.2g/kg (15g for a 75kg adult) per day, and increase dosage by 0.2g/kg every two days, until they reach 0.8g/kg per day, which they take for the remainder of the 6-week period.
Study NCT00575848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will consume placebo twice daily, once with breakfast and once with dinner. The placebo is in liquid form. They will be instructed to refrigerate the liquid until the time that they take it. Subjects start by taking 10g per day for the first 2 days. Starting on the 3rd day, subjects take 0.2g/kg (15g for a 75kg adult) per day, and increase dosage by 0.2g/kg every two days, until they reach 0.8g/kg per day, which they take for the remainder of the 6-week period.
Study NCT00755716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: On the quit date (after 2 weeks of Topiramate medication use), subjects also use 21 mg patch for 7 weeks and on week 8 subjects received 14 mg/day for 3 days then 7 mg for 4 days.
Study NCT00977041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Electrodes will be placed over the temporal lobes bilaterally and a ground electrode placed on the left earlobe. EEG activity will be amplified using a Procomp 2 or Nexus amplifier, and EEGer software will be used to provide subjects with feedback. Contingencies will be set such that alpha brain activity will be reinforced, and high beta and theta brain activity will be inhibited. Standard NF training procedures will be used, which involve simply asking subjects to relax while looking at the feedback screen and Do whatever is necessary to make and keep the bar wide. This protocol will be repeated for up to 40 60-minute sessions (that will include 30 minutes of NF training), scheduled at least weekly.
Study NCT01592968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01592968 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS
Study NCT03191344 — intervention group
Intervention type: BEHAVIORAL
Intervention: with IPSS
Description: all patient in one group use IPSS to record the parathyroid status. the other group operation as ordinary. record the parathyroid status in verbal description
Study NCT03209908 — intervention group
Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate
Description: Tenofovir Disoproxil Fumarate was used for the experimental group of pregnancy women in the 32 weeks during pregnancy
Study NCT01390246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion SR
Description: Bupropion SR 150 mg tablet
Study NCT01390246 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: 35-min counseling by trained research nurse
Study NCT04641156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Therapy program added to laser therapy
Description: a supervised physical therapy exercise program for the neck muscles in the form of manual mobilizations for sternocleidomastoid muscle and upper fibers of trapezius in addition to myofascial trigger point release
Study NCT01390246 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: 35-min counseling by trained research nurse
Study NCT01390246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Bupropion SR placebo tablet
Study NCT05805280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intravascular ultrasound-guided group
Description: intravascular ultrasound use
Study NCT01592968 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole-Brain Radiotherapy
Description: Undergo WBRT
Study NCT02227888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N91115
Description: S nitrosoglutathione reductase inhibitor
Study NCT04233411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mycoprotein ingestion
Study NCT04233411 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mycoprotein ingestion
Study NCT02834624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Poractant alfa
Description: Randomized to receive Curosurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
Study NCT05805280 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: angiography-guided group
Description: angiography-guided use
Study NCT02687334 — intervention group
Intervention type: DRUG
Intervention: 100% Oxygen
Description: We will investigate the changes of cerebral oxygenation during anesthesia induction of standard general anesthesia with 100% oxygen
Study NCT02834624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calfactant
Description: Randomized to receive Infasurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist
Study NCT02952235 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SPF50+
Description: Sun protection
Study NCT04689984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Gabapentin, pregabalin, or amitriptyline
Study NCT04689984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: Gabapentin, pregabalin, or amitriptyline
Study NCT04689984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astaxanthin
Description: Astaxanthin 6 mg tablet once daily
Study NCT00357305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study NCT00357305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00357305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00357305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00357305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01149304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline is given for 8 weeks since the evening of the day of intervention with a dose of 400mg applied three times daily (morning, noon, evening).
Study NCT01149304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: Ursodeoxycholic acid is administered for 8 weeks since the evening of the day of intervention. Dosage is 250mg given three times daily (morning, noon, evening).
Study NCT01149304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Enoxaparin with a dose of 40mg is injected subcutaneously once a day for 8 weeks since the evening of the day of intervention after the HDR-brachytherapy.
Study NCT02640729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelotanserin
Description: once daily, oral, 20-mg tablets
Study NCT02640729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily, oral, matching tablets
Study NCT02161718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samidorphan + olanzapine (ALKS 3831)
Description: Oral tablet, taken once daily
Study NCT02161718 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + olanzapine
Description: Oral tablet, taken once daily
Study NCT03089190 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DC7-2
Description: Effects on appetite
Study NCT03089190 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DC7-2 + potato protein isolate
Description: Effects on appetite
Study NCT03089190 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Potato protein isolate
Description: Effects on appetite
Study NCT03089190 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive whey protein, not expected to affect appetite.
Study NCT02015234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL
Description: TNX-102 SL 2.8 mg taken daily at bedtime.
Study NCT01072682 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective cytopheretic device (SCD)
Description: The selective cytopheretic device (SCD) is comprised of tubing, connectors and a hemofilter cartridge. The device is connected in series to a commercially available Continuous Renal Replacement Therapy (CRRT) device. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits.
Study NCT03006406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long term GnRH-a (3.75mg)
Description: patient in this group only receive GnRH-a 3.75 for pituitary down-regulation
Study NCT03006406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long term GnRH-a (3.75mg)
Description: patient in this group only receive GnRH-a 3.75 for pituitary down-regulation
Study NCT03887936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone gel 1.62%
Description: Testosterone gel 1.62%, apply 2 pumps to upper arm and shoulder.
Study NCT03887936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo gel, apply 2 pumps to upper arm and shoulder
Study NCT04629664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FX-322
Description: Active Comparator
Study NCT04629664 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00358267 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial Resection of Inferior Turbinates (PRIT)
Description: PRIT involves surgically removing a small piece off the turbinate, which also reduces its size.
Study NCT00358267 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation (RFA)
Description: RFA involves inserting a special needle into the inferior (lower) turbinate that releases high frequency energy, which produces heat. The energy and heat cause tissue denaturation (protein damage) and vaporization. The vaporization reduces tissue volume, and denaturation causes healing with scar tissue formation and contraction of surrounding tissue. This procedure can be done under local anesthesia at the doctor's office.
Study NCT05419206 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CMV DNA analysis
Description: CMV DNA quantitative viral load levels were studied
Study NCT02926053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical removal of tumor tissue for T cell production
Description: Surgical removal of > 1 cm3 tumor tissue chosen with regards to high rate of success and to minimize the general risks involved in a surgical procedure.
Study NCT02926053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
Study NCT02926053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2 is administered on day -5 to day -1. Maximum dose of 50 mg per administration.
Study NCT02926053 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIL infusion
Description: The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
Study NCT02926053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2 is administered as high-dose bolus infusions (600.000 IU/kg) over a 15 minute period every 8 hours and continuing for up to 5 days (maximum of 15 doses).
Study NCT03634761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Competency based model
Description: Qualified Learning course and workshop to preschool staff combined with monthly on-site coaching at preschool sites to improve overall intervention setting quality and use of evidence bases practices, provided by external expert from habilitation center.
Study NCT03634761 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive program
Description: Comprehensive program of EIBI for Children with ASD supervised by external expert from habilitation center (treatment as usual)
Study NCT03634761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive program
Description: Comprehensive program of EIBI for Children with ASD supervised by external expert from habilitation center (treatment as usual)
Study NCT02138214 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thyroidectomy
Description: Undergo total thyroidectomy
Study NCT02138214 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: entral lymph node dissection (CLND)
Description: Undergo total thyroidectomy with ipsilateral prophylactic CND
Study NCT02138214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: Voice evaluation, interviews, ancillary studies
Study NCT02138214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-life assessment
Description: Voice evaluation, interviews, ancillary studies
Study NCT03965052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 179
Description: * Generic name: Travoprost~* Distinctive denomination: Bristrio® (PRO-179)~* Active principles: Travoprost 0.004%.~* Pharmaceutical form: Ophthalmic solution~* Presentation: multi-dose dropper bottle, 2.5 milliliters.~* Prepared by: Sophia Laboratories, S.A. of C.V.~* Description of the solution: transparent solution, free of visible particles.~* Description of container: White bottle with 5 milliliters capacity, made of low density polyethylene.
Study NCT03965052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travatan 0.004 % Ophthalmic Solution
Description: * Generic name: Travoprost~* Distinctive denomination: Travatan®~* Active ingredients: Travoprost 0.004%~* Pharmaceutical form: Ophthalmic solution.~* Presentation: multi-dose dropper bottle, 2.5 milliliters.~* Prepared by: Alcon Laboratories Inc.~* Description of the solution: transparent solution, free of visible particles.~* Consult information to prescribe.
Study NCT02682654 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dr. Scholl's Prototype Ankle Brace
Description: Subjects will be instructed to wear the assigned Ankle/Knee brace for 8 ± 2 hours per day, for a minimun of 5 days out of a 7-day/1 week wear period.
Study NCT02682654 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dr. Scholl's Prototype Knee Brace
Description: Subjects will be instructed to wear the assigned Ankle/Knee brace for 8 ± 2 hours per day, for a minimun of 5 days out of a 7-day/1 week wear period.
Study NCT04442737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D/C/F/TAF FDC
Description: A FDC tablet containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir alafenamide 10 mg will be administered once daily.
Study NCT04442737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D/C/F/TAF FDC
Description: A FDC tablet containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir alafenamide 10 mg will be administered once daily.
Study NCT04442737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAF/FTC FDC
Description: TAF/FTC ARV regimen will be administered once daily.
Study NCT04442737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INI Based Regimen
Description: The integrase (INI) inhibitors (for example, bictegravir, dolutegravir, elvitegravir/cobicistat, and raltegravir) will be administered in combination with TAF/FTC, as appropriate. Regimen may consist of a single tablet regimen or a combination of two separate pills.
Study NCT03115424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxenda
Description: Saxenda is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients. Subjects will be recruited and screened prior to undergoing bariatric surgery. Subjects undergoing SG will be randomized 1:1 at month 3 post surgery to Saxenda, 0.6mg SQ daily, with weekly titration of 0.6mg until maintenance dose of 3mg/daily reached. Subjects will remain on study drug for duration of study (33 months). After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
Study NCT03115424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Subjects will be recruited and screened prior to undergoing bariatric surgery.Subjects undergoing SG will be randomized 1:1 at months 3 post surgery to Placebo, 0.6mg SQ daily, with weekly titration of 0.6mg until maintenance dose of 3mg/daily reached. Subjects will remain on study drug for duration of study (33 months). After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
Study NCT03115424 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: RYGB
Description: Subjects will be recruited and screened prior to undergoing bariatric surgery. After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
Study NCT03378596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-citrulline + L-arginine
Description: L-citrulline + L-arginine - sachet dissolved in water
Study NCT03378596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-arginine
Description: L-arginine - sachet dissolved in water
Study NCT03378596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-citrulline
Description: L-citrulline - sachet dissolved in water
Study NCT03378596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo (corn starch) - sachet dissolved in water
Study NCT02569047 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atraumatic Restorative Treatment
Description: No local anaesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with Glass Ionomer Cement (GIC).The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed.
Study NCT02569047 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hall Technique
Description: It employs the cementation of preformed metal crowns (PMC) without the need of any prior teeth preparation or caries removal. No local anesthesia is used neither tooth preparation.Different sizes of PMCs will be tested until the smallest size that perfectly fit the tooth is achieved. The PMC will be loaded with the dental material glass ionomer cement (GIC) and placed. Child will asked to bite firmly on it, until it is fitted. The excess of GIC will be removed with hand instruments and dental floss.
Study NCT01494779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: single subcutaneous dose of 5mg
Study NCT01494779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin
Description: single subcutaneous dose of 5mg
Study NCT01826825 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive Screen
Description: Cognitive Screen
Study NCT01826825 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mini-Cog
Description: Cognitive Screen
Study NCT00517920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-869
Description: 0.25 mg/kg QD
Study NCT00142909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine
Description: Participants will receive lofexidine. The dosing will be initiation at 0.4 mg bid and increased to 0.8mg in week 1 and 1.0 and 1.2 mg bid in week 2, and maintained at 1.2mg bid for weeks 3 to 12. They are then tapered down to 0 over the course of four days in week 12. While the target dose will be 2.4 mg daily, if any subject shows reduced tolerability at this or a lower dose, the dose will be adjusted to the maximum tolerated dose for that subject.
Study NCT00142909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lofexidine Placebo
Study NCT00289796 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTPa-HBV-IPV/Hib
Description: GSK Biologicals' combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b conjugate vaccine
Study NCT02669186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine + Fentanyl
Description: General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain fentanyl + bupivacaine titrated to appropriate surgical conditions and post-operative pain control.